ALKERMES | ALKS - 普通股股本

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 6.02B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	普通股股本	更改		日
AbbVie	USD 1.77B		1.75B	2025-06
Acadia Pharmaceuticals	USD 169.18M		470K	2025-12
ALKERMES	USD 166.46M		855K	2026-03
Amgen	USD 540M		1000K	2026-03
Biogen	USD 146.7M		200K	2025-09
BioMarin Pharmaceutical	USD 193.27M		969K	2026-03
Bristol-Myers Squibb	USD 2.04B		1.74B	2025-09
Coherus Biosciences	USD 121.16M		4.92M	2025-12
Eli Lilly	USD 943.5M		3.33M	2026-03
Gilead Sciences	USD 1.24B		1000K	2026-03
Heron Therapeutics	USD 188.31M		4.99M	2025-12
Ionis Pharmaceuticals	USD 165.9M		3.93M	2026-03
J&J	USD 2.41B		1.74M	2025-12
Malin Corporation	EUR 200K		0	2024-12
Merck	USD 2.47B		12.72M	2025-12
Minerva Neurosciences	USD 1000		0	2024-09
Nektar Therapeutics	USD 20.38M		20.36M	2025-12
Neurocrine Biosciences	USD 100.6M		500K	2026-03
Otsuka Holdings	JPY 527.31M		824K	2026-03
Ovoca Bio	EUR 29.49M		18.43M	2025-06
Pfizer	USD 5.7B		13M	2026-03
Regeneron Pharmaceuticals	USD 105M		300K	2026-03
Vertex Pharmaceuticals	USD 254.2M		200K	2026-03